Company Snapshot

Investment Thesis

Gilead Sciences develops therapies for HIV, viral hepatitis, oncology, and inflammatory diseases, pairing antiviral expertise with a growing oncology and cell therapy portfolio.

  • HIV Leadership: Biktarvy anchors a durable HIV franchise while long-acting lenacapavir offers future growth optionality.
  • Oncology Momentum: Trodelvy expands into earlier lines of breast and lung cancer, complemented by magrolimab and other pipeline assets.
  • Cell Therapy: Yescarta and Tecartus maintain leading positions in CAR-T for lymphoma and leukemia with expanding label opportunities.

Therapeutic Highlights

HIV Franchise Biktarvy remains the leading single-tablet regimen with strong adherence and switching share
Oncology Expansion Trodelvy growth and pipeline readouts support diversification beyond antivirals
Cell Therapy Yescarta and Tecartus generate growing revenue with expanding manufacturing capacity
Long-Acting Pipeline Lenacapavir and capsid inhibitors extend HIV leadership into prevention and treatment

Insights based on Gilead 2024 earnings reports and pipeline updates.

Recent Performance

MTD +1.29%
QTD +9.17%
YTD +32.06%
5Y +102.67%

Gilead trades below peers as investors await oncology catalysts, creating upside leverage if Trodelvy indications and lenacapavir timelines deliver.

Strategic Insights

Durable Virology Cash Flows

HIV and Hepatitis franchises supply cash for business development and pipeline investment.

Oncology Scaling

Clinical data in lung, breast, and hematologic cancers aims to expand Trodelvy and cell therapy usage.

Long-Acting Opportunity

Convenient dosing of lenacapavir and future combinations could reshape HIV prevention and treatment markets.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...